Pfizer beats Q3 2026 estimates and lifts its full-year outlook

what happened

Pharmaceutical company Pfizer published its third-quarter 2026 results. Revenue came to $16.58 billion, unchanged from a year earlier and 4.6% above the average analyst estimate compiled by S&P. Adjusted earnings per share were $0.87 against an expected $0.73, which means they beat consensus by 19.3%.

The company raised its full-year revenue guidance to $63 billion at the midpoint, up from $61.5 billion, an increase of 2.4%. The adjusted EPS outlook was lifted to $3 at the midpoint, a rise of 3.4%. The quarterly operating margin narrowed to 20.4% from 35.3% a year earlier.

Analysts expect revenue to fall 5.1% over the next 12 months and EPS to drop 9.1%, from $3.05 to $2.77, according to S&P. Pfizer's market capitalization stands at $174.8 billion. After the release the shares fell 1.1% to $30.48.

why it matters

The quarter looks stronger than forecasts, but the share reaction suggests some investors wanted more. For the market, the key mix is a beat and higher guidance alongside flat revenue, a shrinking margin and expected declines in the coming year.

market impact

Pfizer shares: the earnings beat and higher guidance support the stock, while weak margins and expected declines weigh on it

• ↔Pfizer shares mixed — earnings beat and raised guidance against flat revenue and a falling margin

tags

instruments